AstraZeneca (AZN)
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business